M
Michael O'Doherty
Researcher at King's College London
Publications - 264
Citations - 15372
Michael O'Doherty is an academic researcher from King's College London. The author has contributed to research in topics: Positron emission tomography & Fluorodeoxyglucose. The author has an hindex of 60, co-authored 264 publications receiving 14116 citations. Previous affiliations of Michael O'Doherty include Kantonsspital St. Gallen & Guy's and St Thomas' NHS Foundation Trust.
Papers
More filters
Journal ArticleDOI
FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0
Ronald Boellaard,Michael O'Doherty,Wolfgang A. Weber,Felix M. Mottaghy,Markus Nowak Lonsdale,Sigrid Stroobants,Wim J.G. Oyen,Joerg Kotzerke,Otto S. Hoekstra,Jan Pruim,Paul Marsden,Klaus Tatsch,Corneline J. Hoekstra,Eric P. Visser,Bertjan Arends,Fred J. Verzijlbergen,Josée M. Zijlstra,Emile F.I. Comans,Adriaan A. Lammertsma,Anne M. J. Paans,Antoon T. M. Willemsen,Thomas Beyer,Andreas Bockisch,Cornelia M. Schaefer-Prokop,Dominique Delbeke,Richard P. Baum,Arturo Chiti,Bernd J. Krause +27 more
TL;DR: This guideline will address general information about [18F]-fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET/CT) and is provided to help the physician and physicist to assist to carrying out, interpret, and document quantitative FDG PET/CT examinations.
Journal ArticleDOI
Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group
Sally F. Barrington,N. George Mikhaeel,Lale Kostakoglu,Michel Meignan,Martin Hutchings,Stefan P. Müeller,Lawrence H. Schwartz,Emanuele Zucca,Richard I. Fisher,Judith Trotman,Otto S. Hoekstra,Rodney J. Hicks,Michael O'Doherty,Roland Hustinx,Alberto Biggi,Bruce D. Cheson +15 more
TL;DR: This article comprises the consensus reached to update guidance on the use of PET-CT for staging and response assessment for [18F]fluorodeoxyglucose-avid lymphomas in clinical practice and late-phase trials.
Journal ArticleDOI
Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma.
John Radford,Timothy M Illidge,Nicholas Counsell,Barry W. Hancock,R. Pettengell,Peter Johnson,Jennie Z Wimperis,Dominic Culligan,Bilyana Popova,Paul Smith,Andrew McMillan,Alison Brownell,Anton Kruger,Andrew Lister,Peter Hoskin,Michael O'Doherty,Sally F. Barrington +16 more
TL;DR: Patients with early-stage Hodgkin's lymphoma and negative PET findings after three cycles of ABVD had a very good prognosis either with or without consolidation radiotherapy, and the noninferiority of the strategy of no further treatment after chemotherapy with regard to progression-free survival did not show.
Journal ArticleDOI
Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin’s Lymphoma
Peter Johnson,Massimo Federico,Amy A Kirkwood,Alexander Fosså,Leanne Berkahn,Angelo Michele Carella,Francesco d'Amore,Gunilla Enblad,Antonella Franceschetto,Michael J. Fulham,Stefano Luminari,Michael O'Doherty,Pip Patrick,Thomas Roberts,Gamal Sidra,L. Stevens,Paul Smith,Judith Trotman,Z. Viney,John Radford,Sally F. Barrington +20 more
TL;DR: Although the results fall just short of the specified noninferiority margin, the omission of bleomycin from the ABVD regimen after negative findings on interim PET resulted in a lower incidence of pulmonary toxic effects than with continued ABVD but not significantly lower efficacy.
Journal ArticleDOI
99Tcm sestamibi--a new agent for parathyroid imaging.
TL;DR: The higher uptake of sestamibi and better imaging properties of its 99Tcm radiolabel means that the agent may replace thallium for routine preoperative parathyroid localization.